ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 1 filers reported holding ACCELERON PHARMA INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $42,813,000 | +577.8% | 248,768 | +394.3% | 0.02% | +525.0% |
| Q2 2021 | $6,316,000 | +1.3% | 50,331 | +9.5% | 0.00% | 0.0% |
| Q1 2021 | $6,235,000 | +78.8% | 45,977 | +68.6% | 0.00% | +100.0% |
| Q4 2020 | $3,488,000 | -43.9% | 27,263 | -50.7% | 0.00% | -50.0% |
| Q3 2020 | $6,217,000 | -30.8% | 55,253 | -41.4% | 0.00% | -42.9% |
| Q2 2020 | $8,981,000 | +127.4% | 94,265 | +114.5% | 0.01% | +75.0% |
| Q1 2020 | $3,949,000 | +25.0% | 43,941 | -26.2% | 0.00% | +33.3% |
| Q4 2019 | $3,159,000 | +7.9% | 59,571 | -19.6% | 0.00% | +50.0% |
| Q3 2019 | $2,929,000 | -20.8% | 74,120 | -17.7% | 0.00% | 0.0% |
| Q2 2019 | $3,699,000 | +149.8% | 90,030 | +183.1% | 0.00% | 0.0% |
| Q1 2019 | $1,481,000 | -76.9% | 31,801 | -78.4% | 0.00% | -66.7% |
| Q4 2018 | $6,407,000 | +531.2% | 147,135 | +729.0% | 0.01% | – |
| Q3 2018 | $1,015,000 | +7.2% | 17,748 | -9.1% | 0.00% | -100.0% |
| Q2 2018 | $947,000 | -37.6% | 19,517 | -49.7% | 0.00% | 0.0% |
| Q1 2018 | $1,518,000 | -30.7% | 38,809 | -24.8% | 0.00% | -50.0% |
| Q4 2017 | $2,192,000 | -93.5% | 51,637 | -94.3% | 0.00% | -92.6% |
| Q3 2017 | $33,525,000 | +3900.6% | 898,293 | +3158.0% | 0.03% | +2600.0% |
| Q2 2017 | $838,000 | +54.9% | 27,572 | +34.7% | 0.00% | – |
| Q1 2017 | $541,000 | -77.9% | 20,470 | -78.6% | 0.00% | -100.0% |
| Q4 2016 | $2,444,000 | +487.5% | 95,784 | +733.1% | 0.00% | – |
| Q3 2016 | $416,000 | +26.1% | 11,497 | +18.4% | 0.00% | – |
| Q2 2016 | $330,000 | -41.9% | 9,714 | -54.8% | 0.00% | -100.0% |
| Q1 2016 | $568,000 | +14.5% | 21,491 | +111.4% | 0.00% | – |
| Q4 2015 | $496,000 | +313.3% | 10,165 | +110.9% | 0.00% | – |
| Q3 2015 | $120,000 | -63.2% | 4,819 | -53.3% | 0.00% | – |
| Q2 2015 | $326,000 | -33.2% | 10,317 | -19.5% | 0.00% | – |
| Q1 2015 | $488,000 | -23.5% | 12,813 | -21.8% | 0.00% | -100.0% |
| Q4 2014 | $638,000 | +340.0% | 16,377 | +241.2% | 0.00% | – |
| Q3 2014 | $145,000 | +21.8% | 4,800 | +36.6% | 0.00% | – |
| Q2 2014 | $119,000 | -21.2% | 3,515 | -19.6% | 0.00% | – |
| Q1 2014 | $151,000 | -27.1% | 4,373 | -16.0% | 0.00% | – |
| Q4 2013 | $207,000 | – | 5,209 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |